Repurposing photographic technology into cosmetics: the Astalift skincare brand (2007)
Re-reading a fading technology as an asset in another market
The heart of this decision lies in the fact that, rather than discarding the technology of a fading business, Fujifilm re-read it as an asset for an entirely different market. Photographic film and skincare are products from separate worlds that never sit side by side on a store shelf. Yet Fujifilm did not overlook the facts that the raw material of film is collagen, and that the antioxidant and nanotechnology techniques used to keep colours from fading carry over to the care of skin. The distinctive feature of this decision is the imaginative reach that bridged the loss of the core business to a new line of trade through a single move — taking inventory of its technological assets.
That said, a chemical maker was by no means guaranteed success in cosmetics, a consumer product. To challenge a mature market where specialist majors compete, armed only with a story about technology, ran no small risk of being buried. Even so, Astalift embodied technology-transfer diversification as an actual product, and became one step on the way to the later life-sciences business. What does a company possess, and in which market can it put that to use — the question posed by a company that had lost photography, its mainstay, remains rich in suggestion for thinking about what one can leave behind when a business’s life runs out.
Revenue and net margin, FY2002–FY2012
Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2007 onwards — after it was taken.
Source: securities reports
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Fujifilm Holdings
- 2004 Restructuring for the death of the core business: VISION75 and the second founding (2004)
- 2008 Acquiring Toyama Chemical and entering pharmaceuticals (2008)
- 2011 Concentrated investment in biopharmaceutical CDMO and the ¥1-trillion vision (2011)
- 2018 The collapse of the Xerox bid and taking full control of Fuji Xerox (2018)
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Fujifilm Holdings’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/4901/manifest.json | Resource index |
| GET | /api/4901/history.json | History overview |
| GET | /api/4901/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/4901/decisions.json | Management decisions (index) |
| GET | /api/4901/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/4901/executives.json | Executives |
| GET | /api/4901/shareholders.json | Major shareholders |
| GET | /api/4901/financials.json | Financial statements |
| GET | /api/4901/financials-longterm.json | Long-term results |
| GET | /api/4901/segments.json | Business segments |
| GET | /api/4901/regions.json | Sales by region |
| GET | /api/4901/workforce.json | Workforce |